Integral Diagnostics' FY22 result appears to have satisfied Ord Minnett but the broker is cautious heading into FY23 given the unknowns surrounding covid infection waves and inflation.

The broker doubts price rises will help much given strong competition and cuts FY23 and FY24 earnings forecasts by -15%.

Lighten recommendation retained. Target price falls to $2.55 from $2.65.

Sector: Health Care Equipment & Services.

Target price is $2.55.Current Price is $2.92. Difference: ($0.37) - (brackets indicate current price is over target). If IDX meets the Ord Minnett target it will return approximately -15% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2022 Acquisdata Pty Ltd., source FN Arena